Weight Loss
Intermittent fasting tied to increased risk for death from heart disease
A time-restricted eating window of less than 8 hours was associated with increased risk for cardiovascular death, according to study findings presented at the Epidemiology, Prevention, Lifestyle & Cardiometabolic Scientific Sessions.
Hormone therapy may boost weight loss for postmenopausal women on semaglutide
Hormone therapy was associated with an improved weight-loss response for postmenopausal women with overweight or obesity treated with semaglutide, according to cohort study results published in Menopause.
Greater access to obesity drugs puts spotlight on safety
GLP-1 receptor agonists come with known adverse events — some common and some rare — but recent reports by the public of alopecia and suicidal ideation have the FDA investigating.
Top in endocrinology: FDA warns about noninvasive glucose readings; diabetes in children
The FDA issued a warning to people with diabetes not to use smartwatches or smart rings that do not pierce the skin for measuring blood glucose because the readings could be inaccurate.
Investigational monthly obesity drug led to durable weight loss in phase 1 trial
Adults with obesity who received an injectable GIP receptor antagonist/GLP-1 receptor agonist every 4 weeks had a decrease in body weight that was maintained for up to 150 days, according to study findings published in Nature Metabolism.
High physical activity volume, sustained weight loss lowers risk for cardiovascular events
Maintaining high levels of physical activity and weight loss were associated with reduced risks for several cardiovascular events, a study published in JAMA Network Open showed.
VIDEO: Weight loss may decrease postoperative complication risk after lumbar spinal fusion
SAN FRANCISCO — Severe or morbidly obese patients had increased operative times, estimated blood loss and rates of surgical site infection after lumbar spinal fusion vs. patients with lower BMI, according to data presented here.
Beyond weight loss, tirzepatide may also lower high blood pressure: SURMOUNT-1
The dual incretin agonist tirzepatide reduced 24-hour ambulatory BP for adults with obesity-related hypertension, with the effects potentially independent of weight loss, according to data from a planned substudy of the SURMOUNT-1 trial.
Many patients maintain weight loss a year after stopping semaglutide, liraglutide
Over half of patients who stopped taking liraglutide or semaglutide were able to maintain their weight for a year, according to a recent study from Epic Research.
Recent unintentional weight loss linked to increase in short-term cancer risk
Health care professionals who experienced recent weight loss had a significantly higher risk for a cancer diagnosis during the subsequent 12 months, results of a prospective cohort analysis revealed.